TabletsClinical Overview
Carbamazepine is an iminostilbene dibenzazepine antiepileptic on the WHO Model List of Essential Medicines. It voltage- and use-dependently blocks neuronal voltage-gated sodium channels, preventing repetitive neuronal firing and inhibiting spread of seizure discharges. It is the gold-standard first-line agent for trigeminal neuralgia. Indicated for focal (partial) seizures, generalized tonic-clonic seizures, trigeminal neuralgia, and acute mania/bipolar maintenance.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Swallow prolonged-release tablets whole with water, with or after meals to minimize stomach upset. Do not crush or chew CR/PR tablets. Avoid grapefruit and grapefruit juice, which drastically elevates carbamazepine levels. Taper slowly when stopping.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dizziness, ataxia, somnolence, nausea, vomiting, diplopia, blurred vision, hyponatremia. Rare/Severe: Boxed warnings: Serious dermatologic reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, strongly associated with HLA-B*1502 allele), aplastic anemia, agranulocytosis, and hepatotoxicity.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: Severe cutaneous adverse reactions (SJS/TEN); genetic screening for the HLA-B*1502 allele is recommended prior to initiation in patients of Asian ancestry. Black box warning for aplastic anemia and agranulocytosis. Potent inducer of CYP3A4, accelerating its own metabolism (auto-induction) and interacting with oral contraceptives, warfarin, and statins.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Carbamazepine Tablets 100 mg
Carbamazepine is an iminostilbene dibenzazepine antiepileptic on the WHO Model List of Essential Medicines. It voltage- and use-dependently blocks neuronal voltage-gated sodium channels, preventing repetitive neuronal firing and inhibiting spread of seizure discharges. It is the gold-standard first-line agent for trigeminal neuralgia. Indicated for focal (partial) seizures, generalized tonic-clonic seizures, trigeminal neuralgia, and acute mania/bipolar maintenance.
Carbamazepine Prolonged release Tablets 400mg
Carbamazepine is an iminostilbene dibenzazepine antiepileptic on the WHO Model List of Essential Medicines. It voltage- and use-dependently blocks neuronal voltage-gated sodium channels, preventing repetitive neuronal firing and inhibiting spread of seizure discharges. It is the gold-standard first-line agent for trigeminal neuralgia. Indicated for focal (partial) seizures, generalized tonic-clonic seizures, trigeminal neuralgia, and acute mania/bipolar maintenance.